What is ARVN's market cap?

$485.17M, based on the Nov 4 close of $7.42.

What is ARVN's P/E ratio?

52.2× trailing-twelve-month earnings of $9.30M.

Does Arvinas pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ARVN is sold short?

5.6M shares, 10.2% of float, as of Oct 15, 2026.

What sector is ARVN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ARVNHealthcarePharmaceuticals

Arvinas, Inc (ARVN)

$7.42+4.65%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$7.09▼ 27.06% in range

Nov 3, 2025Low $6.82 · High $13.83Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Arvinas closed at $7.42 on Nov 4, up 4.65%, 46.3% below its 52-week closing high. Volume of 1.2M shares was 1.51× its 20-day average (above normal).

Split-adjusted performance: +1.5% over one month, -27.7% over six months, -23.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $249.70M, up 1014.7% from a year earlier, with a net margin of 67.8%.

Short interest was 5.6M shares at the Oct 15 settlement, up 3.8% from the prior report (10.2% of float, 8.2 days to cover).

Market cap$485.2M65.4M shares

Revenue · quarter$249.7M+1014.7% YoY

Diluted EPS$2.58—

P/E · TTM52.2×P/S 1.5×

Net margin67.8%Gross 96.4%

Dividend yieldNone

52-week range6.82 – 13.83−46.3% from high

Volume1.2M1.51× 20-day avg

Volatility · 60d49.4%Annualised

Short % of float10.2%8.2 days to cover

Net cash$567.6MCash $567.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.4%1M +1.5%3M −14.5%6M −27.7%YTD −37.4%1Y −23.7%3Y −50.8%5Y −91.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum48

Revenue growth95

Net margin96

Value (low P/E)19

Size60

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short5.6M+3.8% vs prior

Days to cover8.2Settled Oct 15

% of float10.2%

Short vol. 10d46.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ARVNArvinas	$7.42	+4.65%	−27.7%	+1014.7%	67.8%	52.2	$485.2M
MNPRMonopar Therapeutics	$72.81	+4.18%	+14.0%	—	—	—	$488.7M	Compare
EOLSEvolus	$7.47	+1.36%	+18.2%	+21.2%	−9.6%	—	$493.4M	Compare
AQSTAquestive Therapeutics	$3.80	−2.06%	−10.2%	+38.1%	−165.5%	—	$476.9M	Compare
GYREGyre Therapeutics	$4.44	0.00%	−44.8%	−2.1%	−40.1%	—	$470.8M	Compare
PHATPhathom Pharmaceuticals	$5.68	−1.05%	−55.2%	+71.1%	−16.4%	—	$461.7M	Compare
CTMXCytomX Therapeutics	$2.35	+7.80%	−43.1%	−92.4%	−1457.4%	—	$512.1M	Compare
CBIOCrescent Biopharma	$13.82	+5.82%	−23.5%	—	—	—	$513.4M	Compare
FTHFaeth Therapeutics	$19.99	+1.73%	—	—	—	—	$516.6M	Compare

News about Arvinas

All news →

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research · 1d ago▼ Negative Reasons Why Investors Should Consider Betting on Arvinas StockZacks Investment Research · Oct 13, 2026▲ Positive Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s DiseaseGlobeNewswire Inc. · Oct 7, 2026▲ Positive Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology CandidateGlobeNewswire Inc. · Sep 28, 2026▲ Positive Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s DiseaseGlobeNewswire Inc. · Jun 4, 2026▲ Positive

Quick answers

What does Arvinas do?: Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
What is ARVN's market cap?: $485.17M, based on the Nov 4 close of $7.42.
What is ARVN's P/E ratio?: 52.2× trailing-twelve-month earnings of $9.30M.
Does Arvinas pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ARVN is sold short?: 5.6M shares, 10.2% of float, as of Oct 15, 2026.
What sector is ARVN in?: Healthcare, in the Pharmaceuticals industry.

About Arvinas

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

HQ: New Haven, CT246 employeesListed Sep 27, 2018arvinas.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology